Introduction Of The Medicare Ivig Enhancement Act
Madam Speaker, I rise today to recognize the month of May as GBS/CIDP Awareness Month. I encourage my colleagues to join me in supporting those impacted by CIDP and a related disorder, MMN, by cosponsoring H.R. 2905, the Medicare IVIG…
Madam Speaker, I rise today to recognize the month of May as GBS/CIDP Awareness Month. I encourage my colleagues to join me in supporting those impacted by CIDP and a related disorder, MMN, by cosponsoring H.R. 2905, the Medicare IVIG Enhancement Act.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare and debilitating autoimmune disorder that affects the peripheral nerves. Multifocal Motor Neuropathy (MMN) is a related rare disorder in which one's nerves are attacked by their own immune system. Both conditions have a devastating impact on quality of life and require intensive care.
While CIDP and MMN patients may eventually develop resistance to common treatments and therapies, intravenous immune globulin (IVIG) therapy, a form of plasma therapy, has proven to be a safer and more effective alternative for treatment.
Please join me in supporting the Medicare IVIG Enhancement Act, which would provide CIDP and MMN patients the opportunity to receive IVIG therapy in their homes, which will improve quality of life for patients and caregivers alike.
